Ionis Pharmaceuticals (IONS) News Today $33.32 +0.34 (+1.03%) Closing price 04:00 PM EasternExtended Trading$33.00 -0.32 (-0.96%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Voloridge Investment Management LLC Sells 63,698 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Voloridge Investment Management LLC lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 16.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 316,943 shares of the company's stock after selling 63,698 shares during thMay 27 at 4:46 AM | marketbeat.comWoodline Partners LP Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Woodline Partners LP purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 107,610 shares of the company's stocMay 27 at 4:45 AM | marketbeat.comD. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)D. E. Shaw & Co. Inc. trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 84.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,123 shares of the company's stMay 26 at 3:34 AM | marketbeat.comDecember 2027 Options Now Available For Ionis Pharmaceuticals (IONS)May 25 at 10:16 AM | nasdaq.comHC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS)May 23, 2025 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday.May 22, 2025 | marketbeat.comTwo Sigma Advisers LP Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Two Sigma Advisers LP grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,349,211 shares of the company's stock after purchasMay 22, 2025 | marketbeat.comMillennium Management LLC Raises Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Millennium Management LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 79.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 774,215 shares of the company's stock after purchasing an additional 3May 22, 2025 | marketbeat.comVestal Point Capital LP Acquires New Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Vestal Point Capital LP acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 595,000 shares of the company's stock, valued at approximately $20,801,0May 21, 2025 | marketbeat.com6IONS : Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14...May 20, 2025 | benzinga.comTanaka Capital Management Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Tanaka Capital Management Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 52.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,892 shares of the company's stock afterMay 20, 2025 | marketbeat.comTema Etfs LLC Purchases New Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Tema Etfs LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 56,844 shares of the company's stock, valued at approximately $May 20, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 19.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 237,337 shares of the company's stock after purchasing anMay 20, 2025 | marketbeat.comIonis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglyceridesMay 20, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Ensign Peak Advisors IncEnsign Peak Advisors Inc lessened its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 23.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 53,320 shares of the company's stock aftMay 18, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 63.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investoMay 15, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Raised by Orbimed Advisors LLCOrbimed Advisors LLC grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 21.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,817,347 shares of the company's stock after acquiMay 15, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 368,966 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Jacobs Levy Equity Management Inc. lessened its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 56.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 281,813 shares of the company's stock after sellingMay 15, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendatioMay 15, 2025 | marketbeat.comJ. Goldman & Co LP Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)J. Goldman & Co LP raised its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 607,499 shares of the company's stock after buyingMay 13, 2025 | marketbeat.comHudson Bay Capital Management LP Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Hudson Bay Capital Management LP grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 7.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 821,200 shares of the company's stock after buying an additionalMay 13, 2025 | marketbeat.comNorthern Trust Corp Buys 97,367 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Northern Trust Corp increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 840,271 shares of the company's stock after puMay 13, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 49,967 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Driehaus Capital Management LLC reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 21.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1May 12, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 11, 2025 | insidermonkey.comCaption Management LLC Sells 78,183 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Caption Management LLC decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 93.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,417 shares of the company's stock after selling 78,183 shares during the periodMay 10, 2025 | marketbeat.comDeep Track Capital LP Cuts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Deep Track Capital LP trimmed its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,933,928 sharesMay 9, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Bridgefront Capital LLCBridgefront Capital LLC boosted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 94.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,802 shares of the company's stock after buyingMay 8, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Alyeska Investment Group L.P.Alyeska Investment Group L.P. trimmed its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 11.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,000 shares ofMay 8, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company trimmed its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 7.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 286,279 shares of the company's stoMay 8, 2025 | marketbeat.comIonis to host 2025 virtual Annual Meeting of StockholdersMay 6, 2025 | businesswire.comAnalysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ForecastsMay 5, 2025 | uk.finance.yahoo.comAllostery Investments LP Invests $2.27 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Allostery Investments LP bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 65,000 shares of the company's stock, valued atMay 4, 2025 | marketbeat.comBlueCrest Capital Management Ltd Buys Shares of 26,200 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)BlueCrest Capital Management Ltd purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 26,200 shares of the company's stock, valued at approximately $916,0May 3, 2025 | marketbeat.comPDT Partners LLC Grows Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)PDT Partners LLC boosted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 116.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,994 shares of the company's stock after purchasing an additional 15May 3, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Has $12.98 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Schonfeld Strategic Advisors LLC increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 371,381 shares of the coMay 3, 2025 | marketbeat.comMichael R. Hayden Acquires 15,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockMay 3, 2025 | insidertrades.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Earnings BeatIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Strong EarningsMay 2, 2025 | marketbeat.comHsbc Holdings PLC Invests $2.93 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Hsbc Holdings PLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 83,055 shares of the company's stock, valued at approxiMay 2, 2025 | marketbeat.comTower Research Capital LLC TRC Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Tower Research Capital LLC TRC raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 229.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,157 shares of the company's stoMay 2, 2025 | marketbeat.com7IONS : The Analyst Verdict: Ionis Pharmaceuticals In The Eyes...May 1, 2025 | benzinga.comIonis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...May 1, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Stifel Financial CorpStifel Financial Corp boosted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 211,493 shares of the company's stock after buying an additional 28,98May 1, 2025 | marketbeat.comIonis Pharmaceuticals misses Q1 revenue estimates, raises full-year outlookApril 30, 2025 | investing.comIonis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comSusquehanna Fundamental Investments LLC Invests $7.45 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Susquehanna Fundamental Investments LLC bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 213,015 shares of the company's stock, valueApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 225,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Adage Capital Partners GP L.L.C. lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 45.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 275,000 shares of the company'April 30, 2025 | marketbeat.comIonis Pharmaceuticals Q1 2025 Earnings PreviewApril 29, 2025 | msn.comAquatic Capital Management LLC Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Aquatic Capital Management LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 230,016 shares of the company's stock, valued at approximately $8,041,000. AquatiApril 29, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Price T Rowe Associates Inc. MD decreased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,826,939 shares of theApril 29, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 105,619 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Raymond James Financial Inc. purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 105,619 shares of the company's stock, valued at approximately $April 29, 2025 | marketbeat.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼1.051.03▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼108▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today EXEL News Today NBIX News Today BMRN News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IONS Stock Free IONS Stock Alerts